Compare Heron Therapeutics Inc (HRTX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Marathon Petroleum Corp — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Marathon Petroleum Corp trades at $317.57 (market cap $92.05B). The key difference: Marathon Petroleum Corp is far larger — about 1006.5× Heron Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MPC | |
|---|---|---|
Market Cap | $91.46M | $92.05B |
Sector | Health | Energy |
52-Week High | $1.96 | $315.31 |
52-Week Low | $0.39 | $158.59 |
Enterprise Value | $189.36M | $124.23B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Marathon Petroleum (MPC) trades at $317.00, up 1.41% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 20.58, P/S of 0.7, and ROE of 27.92%, supported by recent earnings beats in Q4 2025 and Q1 2026. Cash flow trends indicate operational strength with $8.25B from operations in 2025, while refining margins drive profitability, as highlighted in recent Zacks reports (July 2026).
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $292.70, though risks include volatile energy markets and rising debt-to-asset ratios. The stock's proximity to resistance at $317 suggests potential consolidation, but sustained refining advantages and institutional support offer upside potential for investors focused on energy sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
